[{"indications": "Indications\u00a0hyperlipidaemias of types IIa, IIb, III, IV, and V in patients who\r\nhave not responded adequately to diet and other appropriate measures;\r\nalso see notes above", "name": "FENOFIBRATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.12 Lipid-regulating drugs", "Fibrates", "FENOFIBRATE"], "cautions": "Cautions\u00a0see under Bezafibrate; liver function tests recommended every 3 months for first year (discontinue\r\ntreatment if significantly raised)", "side-effects": "Side-effects\u00a0see under Bezafibrate; also very rarely hepatitis, pancreatitis, and interstitial pneumopathies", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2852.htm", "doses": ["See preparations below", "initially 3 capsules daily in divided doses; usual range\r\n2\u20134 capsules daily; child 4\u201315 years\r\n1 capsule/20\u00a0kg daily", "initially 1 capsule daily (dose form not appropriate for\r\nchildren or in renal impairment)", "severe hyperlipidaemia, 1 capsule daily (dose form not\r\nappropriate for children or in renal impairment)"], "pregnancy": "Pregnancy\u00a0manufacturers advise avoid\u2014embryotoxicity in animal studies"}]